ziyu zheng, MB

National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
Beijing, Beijing

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 3125 - Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study

  Tuesday, October 1, 2024
  12:45 PM – 2:00 PM ET